MindMed is currently in a high-stakes, pre-revenue development phase, with its valuation heavily contingent on the successful progression of the MM-120 candidate through Phase 3 clinical trials.
Price trend, volume and key moving averages
Trailing total returns as of 11/13/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 9, 2026 | -$0.46+18.3% vs -$0.56 | — vs — |
Q3 2026 Aug 6, 2026 | -$1.44-166.2% vs -$0.54 | — vs — |
Q2 2026 May 7, 2026 | -$0.71-51.1% vs -$0.47 | — vs — |
Q1 2026 Feb 26, 2026 | -$0.51-5.4% vs -$0.48 | — vs — |
Definium Therapeutics NASDAQ: DFTX plans to submit a new drug application to the U.S. Food and Drug Administration for its LSD formulation DT120 in the first half of next year, following positive results from three Phase 3 studies, Chief Medical Officer Daniel Karlin said.
Definium Therapeutics, Inc. reported strong Phase 3 results for DT120 in both GAD and MDD, positioning for an NDA filing in H1 2026. DFTX holds over $1bn in cash, supporting operations into 2030, and is preparing for a potential commercial launch in 2027. Despite class-leading efficacy data and regulatory momentum, I maintain a Hold rating due to high valuation, patent challenges, and uncertain market dynamics.
Definium Therapeutics, Inc. (DFTX) Q3 2026 Earnings Call Transcript
Definium Therapeutics NASDAQ: DFTX plans to file a new drug application for its psychiatric treatment candidate DT120 ODT in the first half of 2027, following positive results from three Phase 3 studies in generalized anxiety disorder and major depressive disorder, executives said on the company's third-quarter earnings call.
Benchmark DFTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Definium Therapeutics, Inc. (DFTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $33.00 | $4.43B | -13.43 | — | — | -54.04% | — | |
| $9.12 | $1.23B | -5.57 | — | — | -212.85% | — | |
| $8.86 | $549.18M | -2.53 | -9561.61% | — | -70.99% | — | |
| $0.19 | $3.14M | -0.21 | -25.96% | -4791.48% | -106.13% | — | |
| $1.91 | $2.16M | -0.47 | — | -8269.53% | -81.74% | — | |
| $20.89 | $319.24M | 29.38 | 13.74% | 4.48% | 12.66% | — |
Definium Therapeutics, Inc. (DFTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Definium Therapeutics, Inc. (DFTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Sep 14, 2026·SEC
Sep 8, 2026·SEC
Aug 12, 2026·SEC
Get notified when DFTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Definium Therapeutics, Inc. (DFTX) stock FAQ — growth, dividends, profitability & financials explained
No. Definium Therapeutics, Inc. (DFTX) reported a net loss of $337.5M over the trailing twelve months.
Definium Therapeutics, Inc. (DFTX) had a return on equity (ROE) of -54.0% over the trailing twelve months. A negative ROE means the company lost money over the period.
Definium Therapeutics, Inc. (DFTX) had negative free cash flow of $190.3M over the trailing twelve months.
